中国循证医学杂志

中国循证医学杂志

痛风慢性期降尿酸治疗的系统评价再评价

查看全文

目的 评价痛风慢性期降尿酸治疗系统评价的方法学偏倚及结论可靠程度。 方法 计算机检索 PubMed、EMbase、The Cochrane Library、Epistemonikos、CBM、WangFang Data 和 CNKI 数据库,搜集公开发表的痛风慢性期降尿酸治疗的系统评价/Meta 分析,检索时限均为建库至 2017 年 4 月 8 日。由 2 名研究者独立筛选文献并提取资料,采用 AMSTAR 工具评价纳入研究的方法学质量,并运用 GRADE 方法对系统评价的结局指标进行证据质量分级。 结果 最终纳入 11 篇系统评价/Meta 分析,所有系统评价均涉及别嘌醇,10 篇涉及非布司他,3 篇涉及苯溴马隆,1 篇涉及丙磺舒。纳入系统评价包含 3 个主要结局指标。10 篇系统评价对纳入原始研究进行了方法学质量评价,其中 8 篇使用 Cochrane risk of bias 偏倚评估工具,2 篇使用其他评价工具。AMSTAR 评价结果显示:4 个系统评价评分≥9 分,其余系统评价评分均≤8 分。GRADE 分级结果显示:20 个结局指标的证据质量为低或极低,10 个结局指标的证据质量为中,2 个结局指标的证据质量为高。 结论 中等质量证据显示非布司他在血尿酸达标方面优于别嘌醇,高质量证据显示两者在急性痛风发生率方面无明显差异,高质量证据显示非布司他安全性优于别嘌醇。其他降尿酸干预尚缺乏来源于系统评价的高质量证据支持。期待未来开展更多科学而严谨的研究,生产更多高质量证据,填补相应空白。

Objective To evaluate the methodological bias and the reliability of the conclusions of systematic reviews (SRs) about urate-lowering therapy (ULT) for chronic gout. Methods PubMed, EMbase, The Cochrane Library, Epistemonikos, CBM, WanFang Data and CNKI databases were electronically searched to collect published systematic reviews and meta-analyses evaluating urate-lowering drugs in chronic gout from inception to April 8th 2017. Two reviewers independently screened literature, extracted data, assessed the methodological quality of included SRs using the AMSTAR tool, and assessed the quality of the body of evidence for each outcome using the GRADE approach. Results A total of 11 relevant SRs were included, containing 3 main outcome measures. All of these SRs contained allopurinol, 10 SRs contained febuxostat, 3 SRs contained benzbromarone and 1 SR contained probenecid. Ten SRs assessed the risk of bias of included original studies. Eight SRs used the" assessing risk of bias”tool recommended by Cochrane Collaboration for this assessment while two used other tools. The assessment results of AMSTAR tool showed: the scores of four SRs were ≥9, and the others were ≤8. GRADE results showed: the quality of the evidence of 20 outcomes was low or very low, 10 outcomes was moderate and two outcomes was high. Conclusion Moderate quality evidence shows that febuxostat is beneficial in achieving target serum uric acid levels when compares to allopurinol, and high quality evidence shows the incidence of gout flares is not significantly different between the two groups. High quality evidence also shows that the safety of febuxostat is better than allopurinol. Evidence of SRs is still insufficient to support the effectiveness and safety of other urate-lowering drugs. We expect that more scientific and rigorous researches will be performed in the future, then more high quality evidence will be produced to fill relevant gaps.

关键词: 痛风; 降尿酸治疗; 系统评价再评价; AMSTAR 工具; GRADE 分级

Key words: Gout; Treatment of acute flares; Overview of systematic review; AMSTAR tool; GRADE

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther, 2010, 12(6): 223.
2. Juraschek SP, Miller ER, Gelber AC. Body mass index, obesity, and prevalent gout in the United States in 1988-1994 and 2007-2010. Arthritis Care Res (Hoboken), 2013, 65(1): 127-132.
3. Kuo CF, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis, 2015, 74(4): 661-667.
4. Robinson PC, Taylor WJ, Merriman TR. Systematic review of the prevalence of gout and hyperuricaemia in Australia. Intern Med J, 2012, 42(9): 997-1007.
5. Winnard D, Wright C, Taylor WJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology (Oxford), 2012, 51(5): 901-909.
6. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis, 2017, 76(1): 29-42.
7. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken), 2012, 64(10): 1431-1446.
8. 刘雅莉, 袁金秋, 杨克虎, 等. 系统评价再评价的制作方法简介及相关资料分析. 中国循证儿科杂志, 2011, 6(1): 58-64.
9. 杨克虎, 刘雅莉, 袁金秋, 等. 发展和完善中的系统评价再评价. 中国循证儿科杂志, 2011, 6(1): 54-57.
10. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol, 2007, 7: 10.
11. Schünemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ, 2008, 336(7653): 1106-1110.
12. 陈耀龙, 姚亮, 杜亮, 等. GRADE 在系统评价中应用的必要性及注意事项. 中国循证医学杂志, 2013, 13(12): 1401-1404.
13. 张琰. 非布索坦治疗痛风疗效及安全性的 Meta 分析. 华西医学, 2009, 24(10): 2599-2602.
14. 党超志. 非布索坦治疗痛风的系统评价. 南宁: 广西医科大学, 2010.
15. 邵莉, 魏丽. 苯溴马隆与别嘌呤醇治疗原发性痛风高尿酸血症疗效与安全性比较的 Meta 分析. 中国循证医学杂志, 2012, 12(6): 722-726.
16. Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev, 2012, 11-CD008653.
17. Faruque LI, Ehteshami-Afshar A, Wiebe N, et al. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum, 2013, 43(3): 367-375.
18. Seth R, Kydd AS, Buchbinder R, et al. Allopurinol for chronic gout. Cochrane Database Syst Rev, 2014, (10): CD006077.
19. Villazor-Isidro EBS, Brojan JCG, Pega-Flores CJR, et al. Urate lowering efficacy of febuxostat versus allopurinol in hyperuricemic patients with gout. Phillippine J Intern Med, 2014, 52: 1.
20. Castrejon I, Toledano E, Rosario MP, et al. Erratum to: Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. Rheumatol Int, 2015, 35(7): 1139.
21. 杨婷, 路敏, 周颖, 等. 非布司他和别嘌醇治疗痛风有效性和安全性的 Meta 分析. 中国临床药理学杂志, 2015, 31(2): 122-126.
22. Borghi C, Perez-Ruiz F. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci, 2016, 20(5): 983-992.
23. 方芳, 王鹏. 非布司他与别嘌呤醇治疗痛风随机对照试验系统评价. 中国药业, 2016, 25(11): 13-18, 19.
24. Seo HJ, Kim KU. Quality assessment of systematic reviews or meta-analyses of nursing interventions conducted by Korean reviewers. BMC Med Res Methodol, 2012, 12: 129.
25. White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med, 2018, 378(13): 1200-1210.
26. Moher D, Tetzlaff J, Tricco AC, et al. Epidemiology and reporting characteristics of systematic reviews. PLoS Med, 2007, 4(3): e78.
27. 李静, 李幼平. 不断完善与发展的 Cochrane 系统评价. 中国循证医学杂志, 2008, 8(9): 742-743.
28. 屈云, 何俐, 刘鸣. Cochrane 系统评价的基本方法. 中国临床康复, 2003, 7(4): 532-533, 536.
29. 中华医学会风湿病学分会. 2016 中国痛风诊疗指南. 中华内科杂志, 2016, 55(11): 892-899.
30. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken), 2012, 64(10): 1447-1461.